Retrospective study based on medical records of patients with multiple myeloma, eligible for stem cell transplantation, who received, first-line, the VTD or TD combination.

The most current treatment of multiple myeloma is based on a combination of drugs, including immunomodulators, proteasome inhibitors, etc. The VTD (bortezomib, thalidomide, and dexamethasone) and TD (thalidomide and dexamethasone) regimens are commonly used as a first-line treatment due to limited resources. The study aimed to compare the proportion of favorable responses, survival, and time to the next treatment between two different treatment approaches. The investigators designed a retrospective study based on medical records of patients with multiple myeloma, eligible for stem cell transplantation, who received, first-line, the VTD or TD combination.

Inclusion Criteria:

• clinical records of patients who were considered eligible for transplant due to their functional status and who were given some treatment strategy comprising a combination of drugs.

Exclusion Criteria:

• Incomplete clinical records
• Clinical records of patients who abandoned treatment or could not continue with the treatment due to economic or distance issues
• Clinical records of patients who presented severe sepsis before the beginning of either treatment

Clinical records of patients diagnosed with multiple myeloma treated at Hospital General de México between 2020 and 2023.

All participants and their information will be managed by intern investigators and will be kept secure for personal data protection according to Mexican laws.